Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan

Microbial Pathogenesis

Volumn 64, Issue , 2013, Pages 23-32

  Hausner, Marius ^a   Schamberger, Anna ^a   Naumann, Wolfgang ^a   Jacobs, Enno ^a   Dumke, Roger ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Adhesin; Community acquired pneumonia; Mycoplasma pneumoniae; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; CHITOSAN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; MYCOPLASMA PNEUMONIAE ANTIBODY; PROTEIN P1; PROTEIN P30; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN HP14 30; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; BACTERIUM ADHERENCE; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GUINEA PIG; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RESPIRATORY TRACT MUCOSA; UPPER RESPIRATORY TRACT;

ADHESIN; COMMUNITY-ACQUIRED PNEUMONIA; MYCOPLASMA PNEUMONIAE; VACCINATION;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL ADHESION; BACTERIAL LOAD; BACTERIAL VACCINES; CHITOSAN; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GUINEA PIGS; HELA CELLS; HUMANS; INJECTIONS, SUBCUTANEOUS; LUNG; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; RECOMBINANT PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84882968313     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2013.07.004     Document Type: Article

References (45)

1. Waites K.B., Talkington D.F. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004, 17:697-728.
2. Atkinson T.P., Balish M.F., Waites K.B. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008, 32:956-973.
3. von Baum H., Welte T., Marre R., Suttorp N., Lück C., Ewig S. Mycoplasma pneumoniae pneumonia revisited within the German competence network for community-acquired pneumonia (CAPNETZ). BMC Infect Dis 2009, 9:62.
4. Tsiodras S., Kelesidis I., Kelesidis T., Stamboulis E., Giamarellou H. Central nervous system manifestations of Mycoplasma pneumoniae infections. JInfect 2005, 51:343-354.
5. Zhao F., Liu G., Wu J., Cao B., Tao X., He L., et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother 2013, 57:1521-1523.
6. Linchevski I., Klement E., Nir-Paz R. Mycoplasma pneumonia vaccine protection efficiency and adverse reactions - systematic review and meta-analysis. Vaccine 2009, 27:2437-2446.
7. Dandekar T., Huynen M., Regula J.T., Ueberle B., Zimmermann C.U., Andrade M.A., et al. Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames. Nucleic Acids Res 2000, 28:3278-3288.
8. Kühner S., van Noort V., Betts M.J., Leo-Macias A., Batisse C., Rode M., et al. Proteome organization in a genome-reduced bacterium. Science 2009, 326:1235-1240.
9. Hames C., Halbedel S., Hoppert M., Frey J., Stülke J. Glycerol metabolism is important for cytotoxicity of Mycoplasma pneumoniae. JBacteriol 2009, 191:747-753.
10. Schmidl S.R., Otto A., Lluch-Senar M., Piñol J., Busse J., Becher D., et al. Atrigger enzyme in Mycoplasma pneumoniae: impact of the glycerophosphodiesterase GlpQ on virulence and gene expression. PLoS Pathog 2011, 7:e1002263.
11. Kannan T.R., Baseman J.B. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci U S A 2006, 103:6724-6729.
12. Krause D.C., Balish M.F. Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae. Mol Microbiol 2004, 51:917-924.
13. Balish M.F., Krause D.C. Mycoplasmas: a distinct cytoskeleton for wall-less bacteria. JMol Microbiol Biotechnol 2006, 11:244-255.
14. Schurwanz N., Jacobs E., Dumke R. Astrategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development. Infect Immun 2009, 77:5007-5015.
15. Romero-Arroyo C.E., Jordan J., Peacock S.J., Willby M.J., Farmer M.A., Krause D.C. Mycoplasma pneumoniae protein P30 is required for cytadherence and associated with proper cell development. JBacteriol 1999, 181:1079-1087.
16. Lamm M.E. Interaction of antigens and antibodies at mucosal surfaces. Ann Rev Microbiol 1997, 51:311-340.
17. Arca H., Günbeyaz M., Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009, 8:937-953.
18. Pavot V., Rochereau N., Genin C., Verrier B., Paul S. New insights in mucosal vaccine development. Vaccine 2012, 30:142-154.
19. Dumke R., Schurwanz N., Jacobs E. Characterisation of subtype and variant-specific antigen regions of the P1 adhesin of Mycoplasma pneumoniae. Int J Med Microbiol 2008, 298:483-491.
20. Dumke R., Schurwanz N., Lenz M., Schuppler M., Lück C., Jacobs E. Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach. JClin Microbiol 2007, 45:2726-2730.
21. Berger J., Reist M., Mayer J.M., Felt O., Gurny R. Structure and interactions in chitosan hydrogels by complexation or aggregation for biomedical application. Eur J Pharm Biopharm 2004, 57:35-52.
22. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1982, 15:25-35.
23. Waring A.L., Halse T.A., Csiza C.K., Carlyn C.J., Arruda Musser K., Limberger R.J. Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State. JClin Microbiol 2001, 39:1385-1390.
24. Klement E., Talkington D.F., Wasserzug O., Kayouf R., Davidovitch N., Dumke R., et al. Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease. Clin Infect Dis 2006, 43:1239-1245.
25. Walter N.D., Grant G.B., Bandy U., Alexander N.E., Winchell J.M., Jordan H.T., et al. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness. JInfect Dis 2008, 198:1365-1374.
26. Sliman J.A., Metzgar D., Asseff D.C., Coon R.G., Faix D.J., Lizewski S. Outbreak of acute respiratory disease caused by Mycoplasma pneumoniae on board a deployed U.S. navy ship. JClin Microbiol 2009, 47:4121-4123.
27. Pereyre S., Renaudin H., Charron A., Bébéar C. Clonal spread of Mycoplasma pneumoniae in primary school, Bordeaux, France. Emerg Infect Dis 2012, 18:343-345.
28. Barile M.F. Immunization against Mycoplasma pneumoniae disease: a review. Isr J Med Sci 1988, 20:912-915.
29. Barile M.F., Chandler D.K., Yoshida H., Grabowski M.W., Razin S. Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines. Infect Immun 1988, 56:2450-2457.
30. Couch R.B., Cate T.R., Chanock R.M. Infection with artificially propagated Eaton agent (Mycoplasma pneumoniae). Implications for development of attenuated vaccine for cold agglutinin-positive pneumonia. JAm Med Assoc 1964, 187:442-447.
31. Smith C.B., Friedewald W.T., Chanock R.M. Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers. JAm Med Assoc 1967, 199:353-358.
32. Rottem S. Interaction of mycoplasmas with host cells. Physiol Rev 2003, 83:417-432.
33. Su C.J., Chavoya A., Dallo S.F., Baseman J.B. Sequence divergency of the cytadhesin gene of Mycoplasma pneumoniae. Infect Immun 1990, 58:2669-2674.
34. Layh-Schmitt G., Himmelreich R., Leibfried U. The adhesin related 30-kDa protein of Mycoplasma pneumoniae exhibits size and antigen variability. FEMS Microbiol Lett 1997, 152:101-108.
35. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol 2003, 293:3-15.
36. Oliveira M.L., Areas A.P., Ho P.L. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev Vaccines 2007, 6:419-429.
37. Lee J.W., Park J.H., Robinson J.R. Bioadhesive-based dosage forms: the next generation. JPharm Sci 2000, 89:850-866.
38. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51:81-96.
39. Ralli-Jain P., Tifrea D., Cheng C., Pal S., de la Maza L.M. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 2010, 28:7659-7666.
40. Crouch C.F., Daly J., Henley W., Hannant D., Wilkins J., Francis M.J. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses. Vet Immunol Immunopathol 2005, 108:345-355.
41. McCluskie M.J., Weeratna R.D., Payette P.J., Davis H.L. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002, 32:179-185.
42. Davenport M.P., Grimm M.C., Lloyd A.R. Ahoming selection hypothesis for T-cell trafficking. Immunol Today 2000, 21:315-317.
43. Bellanti J.A., Zeligs B.J., Mendez-Inocencio J., Garcia-Garcia M.L., Islas-Romero R., Omidvar B., et al. Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine. Vaccine 2004, 22:1214-1220.
44. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev Vaccines 2008, 7:1257-1276.
45. Baudner B.C., Verhoef J.C., Giuliani M.M., Peppoloni S., Rappuoli R., del Giudice G., et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. JDrug Target 2005, 13:489-498.